Agenus (NASDAQ:AGEN) Rating Increased to Hold at Zacks Research

Key Points

• Agenus has been upgraded to a "hold" rating by Zacks Research, while B. Riley and HC Wainwright have given the stock a "buy" rating.
• The company reported a loss of $1.00 EPS for the last quarter, missing analysts' expectations, with revenue of $25.70 million against a consensus estimate of $49.71 million.
• Currently, Agenus has a consensus rating of "Moderate Buy" with an average price target of $15.50 from multiple analysts.

Zacks Research upgraded shares of Agenus (NASDAQ:AGEN - Free Report) to a hold rating in a research note released on Tuesday, August 12th,Zacks.com reports.

A number of other brokerages also recently commented on AGEN. B. Riley restated a "buy" rating on shares of Agenus in a research note on Monday, April 21st. Robert W. Baird increased their price target on Agenus from $4.00 to $6.00 and gave the stock a "neutral" rating in a research note on Wednesday, June 4th. HC Wainwright raised Agenus from a "neutral" rating to a "buy" rating and set a $25.00 price target for the company in a research note on Wednesday, June 4th. Finally, Wall Street Zen raised Agenus from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Two analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $15.50.

Agenus Price Performance

Shares of AGEN stock remained flat at $4.53 on Tuesday. The company had a trading volume of 345,488 shares, compared to its average volume of 830,481. The company has a market cap of $144.33 million, a P/E ratio of -0.63 and a beta of 1.62. The stock's fifty day moving average is $5.34 and its two-hundred day moving average is $3.71. Agenus has a twelve month low of $1.38 and a twelve month high of $7.34.

Agenus (NASDAQ:AGEN - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The biotechnology company reported ($1.00) EPS for the quarter, missing analysts' consensus estimates of ($0.78) by ($0.22). The company had revenue of $25.70 million during the quarter, compared to analysts' expectations of $49.71 million. On average, analysts predict that Agenus will post -12.55 earnings per share for the current fiscal year.

Institutional Trading of Agenus

Several institutional investors have recently modified their holdings of AGEN. Bank of Montreal Can acquired a new stake in shares of Agenus in the fourth quarter valued at $69,000. Barclays PLC lifted its holdings in shares of Agenus by 17.7% in the fourth quarter. Barclays PLC now owns 32,737 shares of the biotechnology company's stock valued at $90,000 after buying an additional 4,924 shares during the period. Gilead Sciences Inc. purchased a new stake in shares of Agenus during the fourth quarter valued at $635,000. Northern Trust Corp lifted its holdings in shares of Agenus by 14.8% during the fourth quarter. Northern Trust Corp now owns 208,933 shares of the biotechnology company's stock valued at $572,000 after purchasing an additional 26,870 shares during the last quarter. Finally, B. Riley Financial Inc. purchased a new stake in shares of Agenus during the fourth quarter valued at $2,074,000. Institutional investors and hedge funds own 61.46% of the company's stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.